Xilio Therapeutics (NASDAQ: XLO) furnishes Q2 2025 results and highlights

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Xilio Therapeutics, Inc. furnished an update on its business by announcing financial results for the quarter ended June 30, 2025 and related business highlights. The company did this through a press release dated August 14, 2025, which is attached as Exhibit 99.1.

The press release and related information are furnished, not filed, meaning they are not subject to certain Exchange Act liabilities and are only incorporated into other filings if specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

08/14/2025 - 07:35 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 14, 2025

Xilio Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-40925

85-1623397

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

828 Winter Street, Suite 300

Waltham, Massachusetts

02451

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (857) 524-2466

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange

on which registered

Common stock, par value $0.0001 per share

XLO

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit relating to Item 2.02 of this Current Report on Form 8-K shall be deemed to be furnished and not filed.


Exhibit No.		Description
99.1		Press release issued by Xilio Therapeutics, Inc. on August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	XILIO THERAPEUTICS, INC.

Date: August 14, 2025	By:	/s/ Caroline Hensley
		Caroline Hensley
		Chief Legal Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Xilio Therapeutics (XLO) disclose in its latest Form 8-K?

Xilio Therapeutics furnished an update announcing its financial results for the quarter ended June 30, 2025. The company provided these results and other business highlights through a press release attached as Exhibit 99.1 to the Form 8-K filed on August 14, 2025.

Which reporting period is covered by Xilio Therapeutics’ August 14, 2025 8-K?

The Form 8-K from Xilio Therapeutics covers financial results for the quarter ended June 30, 2025. These quarterly results, along with other business highlights, are summarized in a press release that is furnished as Exhibit 99.1 and incorporated by reference in the report.

How did Xilio Therapeutics present its Q2 2025 results in the 8-K filing?

Xilio Therapeutics presented its Q2 2025 results by furnishing, rather than filing, a press release as Exhibit 99.1. This means the information is not deemed filed for Section 18 liability and is only incorporated into other filings if specifically referenced there.

What exhibits are included with Xilio Therapeutics’ August 14, 2025 Form 8-K?

The Form 8-K includes Exhibit 99.1, a press release issued on August 14, 2025, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document. Exhibit 99.1 contains the detailed quarterly financial results and business highlights.

Who signed Xilio Therapeutics’ August 14, 2025 Form 8-K?

The Form 8-K was signed on behalf of Xilio Therapeutics by Caroline Hensley, the company’s Chief Legal Officer. Her signature indicates the report was duly authorized under the requirements of the Securities Exchange Act of 1934 for this type of current report.

Is the Xilio Therapeutics Q2 2025 press release considered filed with the SEC?

No, the press release attached as Exhibit 99.1 is expressly described as furnished, not filed. As a result, it is not subject to Section 18 liabilities under the Exchange Act unless specifically incorporated by reference into another Securities Act or Exchange Act filing.